help button home button Endocrine Society Endocrinology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Copyright Permission
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Matsushita, M.
Right arrow Articles by Hirata, Y.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Matsushita, M.
Right arrow Articles by Hirata, Y.
Right arrowPubmed/NCBI databases
*Compound via MeSH
*Substance via MeSH
Hazardous Substances DB
*CALCIUM COMPOUNDS
*CALCIUM, ELEMENTAL
Endocrinology Vol. 144, No. 5 1825-1831
Copyright © 2003 by The Endocrine Society

Urotensin II is an Autocrine/Paracrine Growth Factor for the Porcine Renal Epithelial Cell Line, LLCPK1

Mika Matsushita, Masayoshi Shichiri, Nozomi Fukai, Naoko Ozawa, Takanobu Yoshimoto, Nobuyuki Takasu and Yukio Hirata

Department of Clinical and Molecular Endocrinology (M.M., M.S., N.F., N.O., T.Y., Y.H.), Tokyo Medical and Dental University Graduate School, Tokyo, 113-8519, Japan; and Second Department of Internal Medicine (N.T.), University of Ryukyus, Okinawa 903-0215, Japan

Address all correspondence and requests for reprints to: Yukio Hirata, M.D., Department of Clinical and Molecular Endocrinology, Tokyo Medical and Dental University Graduate School, Yushima 1-5-45, Bunkyo-ku, Tokyo 113-8519, Japan. E-mail: yhirata.cme{at}tmd.ac.jp.

Urotensin-II (UII), a cyclic dodecapeptide with potent cardiovascular effects, has recently been shown to be abundantly expressed in the human kidney and excreted in human urine. To investigate whether UII acts as an autocrine/paracrine growth factor for renal epithelial cells, we have studied the effects of human UII (hUII) on DNA synthesis, cytosolic free Ca2+ concentration ([Ca2+]i), ERK activation, and protooncogene (c-myc) expression in a porcine renal epithelial cell line (LLCPK1). hUII stimulated [3H]thymidine uptake into quiescent cells in a dose-dependent manner (10-9 to 10-7 M); this effect was inhibited by a protein kinase C inhibitor (GF109203X), a MAPK kinase inhibitor (PD98059), and a calcium channel blocker (nicardipine). Neither phosphatidyl inositol-3 kinase inhibitors (LY294002, wortmannin) nor p38 kinase inhibitor (SB203580) affected the hUII-induced DNA syntheses. hUII rapidly (within 5 min) and dose-dependently (10-9 to 10-7 M) increased [Ca2+]i in fura-2-loaded cells. hUII also caused a rapid and transient activation of ERK1/2 and induction of c-myc. LLCPK1 cells expressed UII mRNA and its receptor GPR14 mRNA, as determined by RT-PCR, and released UII-like immunoreactivity into media. Neutralization of endogenous UII by anti-hUII antibody, but not nonimmune serum, significantly suppressed DNA synthesis. These data suggest that hUII is an autocrine/paracrine growth factor for renal epithelial cells via activation of both protein kinase C and ERK1/2 pathways as well as Ca2+ influx via voltage-dependent Ca2+ channels.




This article has been cited by other articles:


Home page
Mol. Pharmacol.Home page
J.-C. Liu, C.-H. Chen, J.-J. Chen, and T.-H. Cheng
Urotensin II Induces Rat Cardiomyocyte Hypertrophy via the Transient Oxidization of Src Homology 2-Containing Tyrosine Phosphatase and Transactivation of Epidermal Growth Factor Receptor
Mol. Pharmacol., December 1, 2009; 76(6): 1186 - 1195.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Endocrinol. Metab.Home page
L. Tian, C. Li, J. Qi, P. Fu, X. Yu, X. Li, and L. Cai
Diabetes-induced upregulation of urotensin II and its receptor plays an important role in TGF-{beta}1-mediated renal fibrosis and dysfunction
Am J Physiol Endocrinol Metab, November 1, 2008; 295(5): E1234 - E1242.
[Abstract] [Full Text] [PDF]


Home page
J EndocrinolHome page
A. E S Abdel-Razik, E. J Forty, R. J Balment, and N. Ashton
Renal haemodynamic and tubular actions of urotensin II in the rat
J. Endocrinol., September 1, 2008; 198(3): 617 - 624.
[Abstract] [Full Text] [PDF]


Home page
Nephrol Dial TransplantHome page
A. Mosenkis, T. M. Danoff, N. Aiyar, J. Bazeley, and R. R. Townsend
Human Urotensin II in the plasma of anephric subjects
Nephrol. Dial. Transplant., April 1, 2007; 22(4): 1269 - 1270.
[Full Text] [PDF]


Home page
HypertensionHome page
T. Watanabe, T. Suguro, T. Kanome, Y.-i. Sakamoto, S. Kodate, T. Hagiwara, S. Hongo, T. Hirano, M. Adachi, and A. Miyazaki
Human Urotensin II Accelerates Foam Cell Formation in Human Monocyte-Derived Macrophages
Hypertension, October 1, 2005; 46(4): 738 - 744.
[Abstract] [Full Text] [PDF]


Home page
Arterioscler. Thromb. Vasc. Bio.Home page
T. Djordjevic, R. S. BelAiba, S. Bonello, J. Pfeilschifter, J. Hess, and A. Gorlach
Human Urotensin II Is a Novel Activator of NADPH Oxidase in Human Pulmonary Artery Smooth Muscle Cells
Arterioscler Thromb Vasc Biol, March 1, 2005; 25(3): 519 - 525.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Endocrinology Endocrine Reviews J. Clin. End. & Metab.
Molecular Endocrinology Recent Prog. Horm. Res. All Endocrine Journals
Copyright © 2003 by The Endocrine Society